|
May 21
|
Sarepta Therapeutics (NasdaqGS:SRPT) Continues Phase 3 Study of ELEVIDYS Gene Therapy in Duchenne
|
|
May 21
|
Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy
|
|
May 20
|
High Growth Tech Stocks In The US Market To Watch
|
|
May 20
|
3 Stocks Investors May Be Undervaluing By Up To 43.5%
|
|
May 19
|
SRPT Q1 Earnings Call: Sarepta Adjusts Guidance After Safety Event and Administrative Delays
|
|
May 19
|
Sarepta reports outcomes from trial of Duchenne muscular dystrophy therapy
|
|
May 15
|
2 Healthcare Stocks to Keep an Eye On and 1 to Ignore
|
|
May 14
|
Bearish: Analysts Just Cut Their Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Revenue and EPS estimates
|
|
May 14
|
Q1 Therapeutics Earnings: United Therapeutics (NASDAQ:UTHR) Impresses
|
|
May 13
|
Sarepta Therapeutics Says Duchenne Muscular Dystrophy Treatment Gets Approval in Japan
|
|
May 13
|
Sarepta Therapeutics Announces Approval in Japan of ELEVIDYS, a Gene Therapy to Treat Duchenne Muscular Dystrophy
|
|
May 11
|
Sarepta Therapeutics, Inc. (SRPT): Among Billionaire Glenn Russell Dubin’s Stock Picks with Huge Upside Potential
|
|
May 9
|
Trump announces trade deal, BoE lowers Bank Rate: Morning Buzz
|
|
May 9
|
Is Sarepta Therapeutics, Inc. (SRPT) The Best Stock That Will Bounce Back?
|
|
May 6
|
Sarepta Therapeutics Announces First Quarter 2025 Financial Results and Recent Corporate Developments
|
|
May 5
|
Earnings To Watch: Sarepta Therapeutics (SRPT) Reports Q1 Results Tomorrow
|
|
May 4
|
Oppenheimer Predicts Up to ~840% Surge for These 2 ‘Strong Buy’ Stocks
|
|
May 1
|
1 of Wall Street’s Favorite Stock on Our Buy List and 2 to Approach with Caution
|
|
Apr 30
|
Geron (GERN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
|
|
Apr 30
|
Why Sarepta Therapeutics, Inc. (SRPT) is Among the Best Oversold NASDAQ Stocks to Buy Right Now
|